175.78
price down icon0.63%   -1.12
pre-market  Vorhandelsmarkt:  176.00   0.22   +0.13%
loading
Schlusskurs vom Vortag:
$176.90
Offen:
$177.25
24-Stunden-Volumen:
313.69K
Relative Volume:
0.66
Marktkapitalisierung:
$10.39B
Einnahmen:
$393.98M
Nettoeinkommen (Verlust:
$-367.45M
KGV:
-27.93
EPS:
-6.293
Netto-Cashflow:
$-460.07M
1W Leistung:
-1.09%
1M Leistung:
+8.51%
6M Leistung:
+25.83%
1J Leistung:
+37.49%
1-Tages-Spanne:
Value
$174.53
$179.20
1-Wochen-Bereich:
Value
$170.37
$179.20
52-Wochen-Spanne:
Value
$111.09
$183.00

Ascendis Pharma A S Adr Stock (ASND) Company Profile

Name
Firmenname
Ascendis Pharma A S Adr
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
1,017
Name
Twitter
Name
Nächster Verdiensttermin
2024-12-13
Name
Neueste SEC-Einreichungen
Name
ASND's Discussions on Twitter

Vergleichen Sie ASND mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ASND
Ascendis Pharma A S Adr
175.78 10.39B 393.98M -367.45M -460.07M -6.293
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
443.54 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
511.92 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
313.13 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
540.76 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
257.51 28.51B 3.81B -644.79M -669.77M -6.24

Ascendis Pharma A S Adr Stock (ASND) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-05 Hochstufung Morgan Stanley Equal-Weight → Overweight
2025-04-16 Eingeleitet RBC Capital Mkts Outperform
2025-01-07 Eingeleitet UBS Buy
2024-09-05 Hochstufung Oppenheimer Perform → Outperform
2024-06-25 Hochstufung TD Cowen Hold → Buy
2024-05-31 Eingeleitet Stifel Buy
2023-12-20 Eingeleitet Jefferies Buy
2023-06-14 Fortgesetzt Credit Suisse Neutral
2023-04-05 Herabstufung Oppenheimer Outperform → Perform
2023-04-04 Herabstufung Morgan Stanley Overweight → Equal-Weight
2023-04-03 Herabstufung Credit Suisse Outperform → Neutral
2022-10-20 Eingeleitet Goldman Buy
2022-08-30 Fortgesetzt Berenberg Buy
2022-03-28 Fortgesetzt Wedbush Outperform
2022-03-15 Hochstufung BofA Securities Neutral → Buy
2022-03-01 Eingeleitet Citigroup Buy
2022-02-14 Hochstufung Oppenheimer Perform → Outperform
2022-01-06 Eingeleitet Cowen Market Perform
2021-12-08 Eingeleitet Wells Fargo Overweight
2021-10-20 Herabstufung BofA Securities Buy → Neutral
2021-03-30 Herabstufung Oppenheimer Outperform → Perform
2021-03-11 Fortgesetzt Stifel Buy
2020-12-17 Eingeleitet Berenberg Buy
2020-09-14 Fortgesetzt JP Morgan Overweight
2020-03-20 Eingeleitet Oppenheimer Outperform
2019-10-11 Eingeleitet Morgan Stanley Overweight
2019-03-25 Eingeleitet Evercore ISI Outperform
2019-01-24 Eingeleitet Cantor Fitzgerald Overweight
2019-01-24 Hochstufung Leerink Partners Mkt Perform → Outperform
2018-06-26 Eingeleitet Stifel Buy
2018-04-02 Bestätigt Leerink Partners Mkt Perform
2017-05-11 Eingeleitet JP Morgan Overweight
2017-03-09 Herabstufung Leerink Partners Outperform → Mkt Perform
2017-02-09 Eingeleitet Credit Suisse Outperform
2016-09-26 Eingeleitet Wedbush Outperform
Alle ansehen

Ascendis Pharma A S Adr Aktie (ASND) Neueste Nachrichten

pulisher
Jun 16, 2025

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

Jun 16, 2025
pulisher
Jun 10, 2025

Canaccord holds Ascendis Pharma stock at $84 target - Investing.com

Jun 10, 2025
pulisher
Jun 09, 2025

BofA raises Ascendis Pharma stock target to $216 - Investing.com

Jun 09, 2025
pulisher
Jun 04, 2025

Ascendis Pharma ADR Scores Relative Strength Rating Upgrade - MSN

Jun 04, 2025
pulisher
Jun 03, 2025

Chagee Holdings ADR Scores Relative Strength Rating Upgrade - inkl

Jun 03, 2025
pulisher
Jun 02, 2025

BofA Securities raises Ascendis Pharma stock price target to $201 - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

European ADRs Climb With Biotech Stocks Leading The Charge - Finimize

Jun 02, 2025
pulisher
Jun 02, 2025

Ascendis Pharma stock rises following FDA priority review By Investing.com - Investing.com India

Jun 02, 2025
pulisher
Jun 02, 2025

Ascendis Pharma stock rises following FDA priority review - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

FDA prioritizes review of Ascendis Pharma’s growth disorder drug - Investing.com

Jun 02, 2025
pulisher
May 27, 2025

Stifel maintains Buy on Ascendis Pharma stock, target at $212 - Investing.com

May 27, 2025
pulisher
May 25, 2025

Ascendis Pharma’s SWOT analysis: strong product pipeline drives stock potential - Investing.com India

May 25, 2025
pulisher
May 15, 2025

Ascendis Pharma grants new employee warrants By Investing.com - Investing.com India

May 15, 2025
pulisher
May 14, 2025

Ascendis Pharma grants new employee warrants - Investing.com

May 14, 2025
pulisher
May 13, 2025

Ascendis Pharma reports growth in achondroplasia trial By Investing.com - Investing.com India

May 13, 2025
pulisher
May 13, 2025

Ascendis Pharma reports growth in achondroplasia trial - Investing.com

May 13, 2025
pulisher
May 12, 2025

Cantor maintains $200 target on Ascendis Pharma stock By Investing.com - Investing.com South Africa

May 12, 2025
pulisher
May 09, 2025

European Stocks Show Mixed Results With Novo Nordisk Leading Gains - Finimize

May 09, 2025
pulisher
May 08, 2025

In the Green: Ascendis Pharma A/S ADR (ASND) Closes at 160.99, Up/Down -1.14 from Previous Day - DWinneX

May 08, 2025
pulisher
May 02, 2025

Ascendis Pharma stock target raised to $245 by JPMorgan - Investing.com

May 02, 2025
pulisher
May 02, 2025

Ascendis Pharma A/S ADR (ASND) stock on the rise: An overview - uspostnews.com

May 02, 2025
pulisher
May 01, 2025

Ascendis Pharma AS earnings missed by €0.11, revenue topped estimates - Investing.com

May 01, 2025
pulisher
Apr 30, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 30, 2025
pulisher
Apr 16, 2025

RBC Capital sets $205 target on Ascendis Pharma stock - Investing.com

Apr 16, 2025
pulisher
Apr 15, 2025

Banco Macro ADR Earns Relative Strength Rating Upgrade - inkl

Apr 15, 2025
pulisher
Apr 14, 2025

Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory (ASND) - Seeking Alpha

Apr 14, 2025
pulisher
Apr 11, 2025

Biotech Stocks To Watch And Pharma Industry News - Investor's Business Daily

Apr 11, 2025
pulisher
Apr 11, 2025

Stocks To Watch: Ascendis Pharma ADR Sees RS Rating Jump To 87 - Investor's Business Daily

Apr 11, 2025
pulisher
Apr 07, 2025

European Equities Traded in the US as American Depositary Receipts Drop in Monday Trading - TradingView

Apr 07, 2025
pulisher
Mar 27, 2025

UBS maintains Ascendis Pharma stock Buy rating, $196 target - Investing.com

Mar 27, 2025
pulisher
Mar 19, 2025

European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading - TradingView

Mar 19, 2025
pulisher
Mar 18, 2025

European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - TradingView

Mar 18, 2025
pulisher
Mar 18, 2025

Ascendis Pharma ADR Joins Elite Club Of Stocks With RS Ratings Over 90 - Investor's Business Daily

Mar 18, 2025
pulisher
Mar 17, 2025

European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading - TradingView

Mar 17, 2025
pulisher
Mar 13, 2025

European Equities Traded in the US as American Depositary Receipts Tread Water in Thursday Trading - TradingView

Mar 13, 2025
pulisher
Mar 12, 2025

European Equities Traded in the US as American Depositary Receipts Lower Wednesday - TradingView

Mar 12, 2025
pulisher
Mar 09, 2025

Ascendis Pharma A/S Sponsored ADR to Host Earnings Call - ACCESS Newswire

Mar 09, 2025
pulisher
Mar 07, 2025

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Up Slightly for Week - TradingView

Mar 07, 2025
pulisher
Mar 06, 2025

Ascendis Pharma at TD Cowen Conference: Strategic Growth in Rare Diseases - Investing.com

Mar 06, 2025
pulisher
Feb 26, 2025

Ascendis Pharma's SWOT analysis: stock outlook amid Yorvipath success, Skytrofa challenges - Investing.com

Feb 26, 2025
pulisher
Feb 25, 2025

Cantor Fitzgerald lifts Ascendis Pharma target to $200, maintains Overweight - Investing.com

Feb 25, 2025
pulisher
Feb 20, 2025

Why Is BioMarin Stock Trading Higher On Thursday? - Benzinga

Feb 20, 2025
pulisher
Feb 20, 2025

Stocks To Watch: Kontoor Brands Sees RS Rating Rise To 84 - Inkl

Feb 20, 2025
pulisher
Feb 19, 2025

Stocks To Watch: Ascendis Pharma ADR Sees RS Rating Rise To 82 - Investor's Business Daily

Feb 19, 2025
pulisher
Feb 18, 2025

Stocks To Watch: Pony AI ADR Sees RS Rating Jump To 92 - Inkl

Feb 18, 2025
pulisher
Feb 17, 2025

Ascendis Pharma's SWOT analysis: promising pipeline fuels stock potential - Investing.com

Feb 17, 2025
pulisher
Feb 13, 2025

ASND’s price-to-free cash flow ratio: A closer look at its relevance - US Post News

Feb 13, 2025
pulisher
Feb 12, 2025

Earnings call transcript: Ascendis Pharma Q4 2024 sees revenue rise - Investing.com

Feb 12, 2025
pulisher
Feb 12, 2025

Ascendis Pharma launches $25 million share buyback - Investing.com

Feb 12, 2025
pulisher
Feb 12, 2025

European Equities Traded in the US as American Depositary Receipts Tread Water in Wednesday Trading - TradingView

Feb 12, 2025
pulisher
Feb 11, 2025

Cantor Fitzgerald maintains Ascendis Pharma Overweight rating By Investing.com - Investing.com South Africa

Feb 11, 2025

Finanzdaten der Ascendis Pharma A S Adr-Aktie (ASND)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.68
price down icon 2.27%
$35.40
price up icon 1.55%
$20.39
price down icon 0.83%
$105.42
price up icon 2.67%
$103.01
price down icon 3.30%
biotechnology ONC
$257.51
price up icon 4.22%
Kapitalisierung:     |  Volumen (24h):